NasdaqGS:EXELBiotechs
How Exelixis’ Earnings Beat and FDA Zanzalintinib Milestone Will Impact Exelixis (EXEL) Investors
Exelixis recently reported quarterly adjusted earnings per share that exceeded expectations, helped by higher Cabometyx volumes and lower operating expenses, while the FDA accepted its New Drug Application for zanzalintinib in metastatic colorectal cancer with a target action date in December 2026.
Alongside these results, the company reiterated its 2026 guidance and benefited from multiple upward analyst earnings estimate revisions, underscoring how regulatory milestones and disciplined...